Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma

James Zabora, Joanne Buzaglo, Vicki Kennedy, Tiffany Richards, Tara Schapmire, Brad Zebrack, Irene M. Ghobrial

Research output: Contribution to journalArticle

Abstract

Objective: A model of psychosocial care specific for patients with multiple myeloma and their caregivers has not yet been proposed. We sought to develop a model of care that considers the specific profile of this disease. Method: The authors, representing a multidisciplinary care team, met in December of 2012 to identify a model of psychosocial care for patients with multiple myeloma and their caregivers. This model was determined by consensus during the meeting and via total agreement following the meeting. The meeting was sponsored by Onyx Pharmaceuticals. Results: The need for targeted psychosocial care for the multiple myeloma patient and caregiver throughout the disease process is essential to ensure quality of life and optimal treatment outcomes. We propose herein the first known model of care for the treatment of multiple myeloma that engages both the patient and their caregivers. Significance of results: Innovative partnerships between psychosocial providers and other entities such as pharmaceutical companies can maximize resources for comprehensive program development. This manuscript proposes a model of care that promotes active engagement in therapies for multiple myeloma while engaging the individual patient and their family caregivers. This treatment approach must be evidence based in terms of distress screening tools, comprehensive psychosocial assessments, and, most importantly, in the interventions and measurements of response that clinicians apply to this population.

Original languageEnglish (US)
Pages (from-to)829-838
Number of pages10
JournalPalliative and Supportive Care
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Multiple Myeloma
Caregivers
Patient Care
Program Development
Pharmaceutical Preparations
Therapeutics
Quality of Life
Population

Keywords

  • Distress
  • Multiple myeloma
  • Psychosocial care
  • Standard of care

ASJC Scopus subject areas

  • Medicine(all)
  • Psychiatry and Mental health
  • Clinical Psychology
  • Nursing(all)

Cite this

Clinical perspective : Linking psychosocial care to the disease continuum in patients with multiple myeloma. / Zabora, James; Buzaglo, Joanne; Kennedy, Vicki; Richards, Tiffany; Schapmire, Tara; Zebrack, Brad; Ghobrial, Irene M.

In: Palliative and Supportive Care, Vol. 13, No. 4, 01.08.2015, p. 829-838.

Research output: Contribution to journalArticle

Zabora, James ; Buzaglo, Joanne ; Kennedy, Vicki ; Richards, Tiffany ; Schapmire, Tara ; Zebrack, Brad ; Ghobrial, Irene M. / Clinical perspective : Linking psychosocial care to the disease continuum in patients with multiple myeloma. In: Palliative and Supportive Care. 2015 ; Vol. 13, No. 4. pp. 829-838.
@article{6b2d476e64e24f2d8422de22636e325d,
title = "Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma",
abstract = "Objective: A model of psychosocial care specific for patients with multiple myeloma and their caregivers has not yet been proposed. We sought to develop a model of care that considers the specific profile of this disease. Method: The authors, representing a multidisciplinary care team, met in December of 2012 to identify a model of psychosocial care for patients with multiple myeloma and their caregivers. This model was determined by consensus during the meeting and via total agreement following the meeting. The meeting was sponsored by Onyx Pharmaceuticals. Results: The need for targeted psychosocial care for the multiple myeloma patient and caregiver throughout the disease process is essential to ensure quality of life and optimal treatment outcomes. We propose herein the first known model of care for the treatment of multiple myeloma that engages both the patient and their caregivers. Significance of results: Innovative partnerships between psychosocial providers and other entities such as pharmaceutical companies can maximize resources for comprehensive program development. This manuscript proposes a model of care that promotes active engagement in therapies for multiple myeloma while engaging the individual patient and their family caregivers. This treatment approach must be evidence based in terms of distress screening tools, comprehensive psychosocial assessments, and, most importantly, in the interventions and measurements of response that clinicians apply to this population.",
keywords = "Distress, Multiple myeloma, Psychosocial care, Standard of care",
author = "James Zabora and Joanne Buzaglo and Vicki Kennedy and Tiffany Richards and Tara Schapmire and Brad Zebrack and Ghobrial, {Irene M.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1017/S1478951514000649",
language = "English (US)",
volume = "13",
pages = "829--838",
journal = "Palliative and Supportive Care",
issn = "1478-9515",
publisher = "Cambridge University Press",
number = "4",

}

TY - JOUR

T1 - Clinical perspective

T2 - Linking psychosocial care to the disease continuum in patients with multiple myeloma

AU - Zabora, James

AU - Buzaglo, Joanne

AU - Kennedy, Vicki

AU - Richards, Tiffany

AU - Schapmire, Tara

AU - Zebrack, Brad

AU - Ghobrial, Irene M.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: A model of psychosocial care specific for patients with multiple myeloma and their caregivers has not yet been proposed. We sought to develop a model of care that considers the specific profile of this disease. Method: The authors, representing a multidisciplinary care team, met in December of 2012 to identify a model of psychosocial care for patients with multiple myeloma and their caregivers. This model was determined by consensus during the meeting and via total agreement following the meeting. The meeting was sponsored by Onyx Pharmaceuticals. Results: The need for targeted psychosocial care for the multiple myeloma patient and caregiver throughout the disease process is essential to ensure quality of life and optimal treatment outcomes. We propose herein the first known model of care for the treatment of multiple myeloma that engages both the patient and their caregivers. Significance of results: Innovative partnerships between psychosocial providers and other entities such as pharmaceutical companies can maximize resources for comprehensive program development. This manuscript proposes a model of care that promotes active engagement in therapies for multiple myeloma while engaging the individual patient and their family caregivers. This treatment approach must be evidence based in terms of distress screening tools, comprehensive psychosocial assessments, and, most importantly, in the interventions and measurements of response that clinicians apply to this population.

AB - Objective: A model of psychosocial care specific for patients with multiple myeloma and their caregivers has not yet been proposed. We sought to develop a model of care that considers the specific profile of this disease. Method: The authors, representing a multidisciplinary care team, met in December of 2012 to identify a model of psychosocial care for patients with multiple myeloma and their caregivers. This model was determined by consensus during the meeting and via total agreement following the meeting. The meeting was sponsored by Onyx Pharmaceuticals. Results: The need for targeted psychosocial care for the multiple myeloma patient and caregiver throughout the disease process is essential to ensure quality of life and optimal treatment outcomes. We propose herein the first known model of care for the treatment of multiple myeloma that engages both the patient and their caregivers. Significance of results: Innovative partnerships between psychosocial providers and other entities such as pharmaceutical companies can maximize resources for comprehensive program development. This manuscript proposes a model of care that promotes active engagement in therapies for multiple myeloma while engaging the individual patient and their family caregivers. This treatment approach must be evidence based in terms of distress screening tools, comprehensive psychosocial assessments, and, most importantly, in the interventions and measurements of response that clinicians apply to this population.

KW - Distress

KW - Multiple myeloma

KW - Psychosocial care

KW - Standard of care

UR - http://www.scopus.com/inward/record.url?scp=84946480618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946480618&partnerID=8YFLogxK

U2 - 10.1017/S1478951514000649

DO - 10.1017/S1478951514000649

M3 - Article

C2 - 24959656

AN - SCOPUS:84946480618

VL - 13

SP - 829

EP - 838

JO - Palliative and Supportive Care

JF - Palliative and Supportive Care

SN - 1478-9515

IS - 4

ER -